Inflammatory bowel disease patients with lower trough levels of infliximab at induction may be less likely to respond to the drug during treatment maintenance, researchers reported in the journal Inflammatory Bowel Diseases. Up to 30% of IBD patients may see a loss of response over 12 months of treatment with infliximab, researchers said.
Infliximab levels at induction may predict long-term response
Sign up for AANP SmartBrief
News for nurse practitioners
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.